Literature DB >> 21060325

Adrenal gland: Congenital adrenal hyperplasia: new treatment guidelines.

Felix G Riepe.   

Abstract

Congenital adrenal hyperplasia is one of the most prevalent genetic endocrine diseases. A new guideline from the endocrine society offers expert opinion and evidence-based recommendations on the diagnosis and management of this challenging condition.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21060325     DOI： 10.1038/nrendo.2010.197

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN： 1759-5029            Impact factor:   43.330


  9 in total

Review 1.  Technical report: congenital adrenal hyperplasia. Section on Endocrinology and Committee on Genetics.

Authors: 
Journal:  Pediatrics       Date:  2000-12       Impact factor: 7.124

Review 2.  Consensus statement on 21-hydroxylase deficiency from the Lawson Wilkins Pediatric Endocrine Society and the European Society for Paediatric Endocrinology.

Authors: 
Journal:  J Clin Endocrinol Metab       Date:  2002-09       Impact factor: 5.958

Review 3.  Clinical review: Adult height in patients with congenital adrenal hyperplasia: a systematic review and metaanalysis.

Authors:  Kalpana Muthusamy; Mohamed B Elamin; Galina Smushkin; Mohammad Hassan Murad; Julianna F Lampropulos; Khalid B Elamin; Nisrin O Abu Elnour; Juan F Gallegos-Orozco; Mitra M Fatourechi; Neera Agrwal; Melanie A Lane; Felipe N Albuquerque; Patricia J Erwin; Victor M Montori
Journal:  J Clin Endocrinol Metab       Date:  2010-09       Impact factor: 5.958

4.  Prenatal diagnosis for congenital adrenal hyperplasia in 532 pregnancies.

Authors:  M I New; A Carlson; J Obeid; I Marshall; M S Cabrera; A Goseco; K Lin-Su; A S Putnam; J Q Wei; R C Wilson
Journal:  J Clin Endocrinol Metab       Date:  2001-12       Impact factor: 5.958

Review 5.  Prenatal dexamethasone use for the prevention of virilization in pregnancies at risk for classical congenital adrenal hyperplasia because of 21-hydroxylase (CYP21A2) deficiency: a systematic review and meta-analyses.

Authors:  M Mercè Fernández-Balsells; Kalpana Muthusamy; Galina Smushkin; Julianna F Lampropulos; Mohamed B Elamin; Nisrin O Abu Elnour; Khalid B Elamin; Neera Agrwal; Juan F Gallegos-Orozco; Melanie A Lane; Patricia J Erwin; Victor M Montori; M Hassan Murad
Journal:  Clin Endocrinol (Oxf)       Date:  2010-10       Impact factor: 3.478

6.  Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline.

Authors:  Phyllis W Speiser; Ricardo Azziz; Laurence S Baskin; Lucia Ghizzoni; Terry W Hensle; Deborah P Merke; Heino F L Meyer-Bahlburg; Walter L Miller; Victor M Montori; Sharon E Oberfield; Martin Ritzen; Perrin C White
Journal:  J Clin Endocrinol Metab       Date:  2010-09       Impact factor: 5.958

7.  Dexamethasone therapy of congenital adrenal hyperplasia and the myth of the "growth toxic" glucocorticoid.

Authors:  Scott A Rivkees
Journal:  Int J Pediatr Endocrinol       Date:  2010-04-15

Review 8.  Recent advances in diagnosis, treatment, and outcome of congenital adrenal hyperplasia due to 21-hydroxylase deficiency.

Authors:  Felix G Riepe; Wolfgang G Sippell
Journal:  Rev Endocr Metab Disord       Date:  2007-12       Impact factor: 6.514

9.  Health status of adults with congenital adrenal hyperplasia: a cohort study of 203 patients.

Authors:  Wiebke Arlt; Debbie S Willis; Sarah H Wild; Nils Krone; Emma J Doherty; Stefanie Hahner; Thang S Han; Paul V Carroll; Gerry S Conway; D Aled Rees; Roland H Stimson; Brian R Walker; John M C Connell; Richard J Ross
Journal:  J Clin Endocrinol Metab       Date:  2010-08-18       Impact factor: 5.958
  9 in total
  1 in total

1.  Mortality in children with classic congenital adrenal hyperplasia and 21-hydroxylase deficiency (CAH) in Germany.

Authors:  Helmuth G Dörr; Hartmut A Wollmann; Berthold P Hauffa; Joachim Woelfle
Journal:  BMC Endocr Disord       Date:  2018-06-08       Impact factor: 2.763
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.